Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
about
New developments in the management of moderate-to-severe hemophilia BEmerging and future therapies for hemophiliaFuture of coagulation factor replacement therapyAchieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futurePresent and future challenges in the treatment of haemophilia: the patient's perspectivePresent and future challanges in the treatment of haemophilia: a clinician's perspectiveExtravascular FIX and coagulationThe History of Clotting Factor Concentrates PharmacokineticsClinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Treatment of hemophilia B: focus on recombinant factor IX.BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BRecombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialRecombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.Advanced therapies for the treatment of hemophilia: future perspectives.New treatments in hemophilia: insights for the clinician.Molecular approaches for improved clotting factors for hemophilia.Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.Evidence of clinically significant extravascular stores of factor IX.The hope and reality of long-acting hemophilia products.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.Haemophilia B: current pharmacotherapy and future directions.The future of hemostasis management.Is haemophilia B less severe than haemophilia A?Advances in the treatment of inherited coagulation disorders.Investigational drugs for coagulation disorders.Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Factor VIII therapy for hemophilia A: current and future issues.Novel products for haemostasis - current status.Changing paradigm of prophylaxis with longer acting factor concentrates.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.Research in haemophilia B--approaching the request for high evidence levels in a rare disease.Individualizing prophylaxis in hemophilia: a review.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
P2860
Q26751323-5195F12B-3E75-44AD-9967-E68D96472A1BQ26781143-B1D7EE91-B011-4C97-90BA-6DD069BE97C6Q26820824-A9FD0025-ADF7-4FD1-A1AF-5D104A2BF8A6Q26853631-2F40BC5A-1E8D-40AA-A3EE-4144866C370CQ27022801-36966A5E-FD56-4D72-BDB6-5F167B0A1AD8Q27026137-E2F2D15A-D661-452A-BD9E-4403614B0FAAQ28079369-9E26A311-F19B-438E-A8B4-6BF7379B9D9FQ30235127-FB83E9D6-9BB7-4BA9-8400-FA1B621ECE4DQ34045763-E65B5CBA-9F3C-4397-A92C-517171B76E90Q34329068-23F84FC5-163B-4330-937B-6DAE50439387Q34348566-1095DCFB-FECE-4FE1-9787-7B2992FEA726Q34737483-C2473D20-E604-4AAA-B67D-14EE3649DCA9Q35692016-D9575090-363E-4100-BCB9-276D3251CB73Q36250920-2478F734-27EC-477A-9C5A-299AFDD38EC4Q36380181-14C18E08-2052-49D8-98FE-892C16ED3BE4Q36552555-A13B726E-3A25-4AAE-9BE7-6826C9F4DC0DQ36612681-88A6B8A2-8AD6-48BD-96E5-5BFDFDD6DE24Q37334700-8F0D1AD7-3BF1-40E7-BC18-9659E20118F1Q37591452-F9E2D998-205D-4AC5-BDB4-D9D87793794EQ37623821-305273BB-0A36-46AB-B72C-30256CAB680FQ37626502-7B2DBE18-3378-45B8-B909-A68179D51628Q37990479-60E6E02E-8E5B-4E2F-A1C9-50B3A578C1F9Q38036746-94999020-5A59-4FBB-AF22-994692D930B5Q38040458-EDE5B4D0-37D9-4EE4-9320-02EA4769F9B9Q38056457-260FC727-2EA8-4C33-92AE-C0E661C52D33Q38091706-860F82D5-F872-444E-B2BF-77BF9B4D4D83Q38100271-0427D950-177C-4BCD-B221-F650768AD2CCQ38106245-63BBFA6A-D60E-47C7-8320-D42EEA6C1471Q38115812-9EA3023B-1AA1-4589-A6ED-317A7B12ACACQ38121644-C7CF97A2-EE94-413B-ABD9-9ECC3D0D777BQ38127745-043E84C1-E7A8-4531-B231-46E42C831B8BQ38203350-CF8865AE-254E-4C1B-9CC0-D362DD28B16CQ38206849-A321F915-DA9D-480C-B3A8-B1E332F06D7CQ38206858-42D56A93-DF60-4DDB-94AB-F6AAA891551FQ38237476-D9794B24-5904-4937-AE31-A0ECD4EE7C34Q38238972-AF70A175-9656-494E-A04E-438B1FAA78BEQ38266890-09B4175C-E21F-4522-975A-03DA7B913B5AQ38286306-7200DEAE-6AC4-4FA4-807A-1D03CC5A5163Q38323857-87BD712C-250E-4D93-8379-ACBA465F3238Q38371071-497CE907-94E1-4A05-92E5-79B7B7F9170D
P2860
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@en
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@nl
type
label
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@en
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@nl
prefLabel
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@en
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@nl
P2093
P921
P1433
P1476
Enhanced pharmacokinetic prope ...... in patients with hemophilia B.
@en
P2093
Andreas Tiede
Claude Negrier
Karin Knobe
Paul Giangrande
P304
P356
10.1182/BLOOD-2011-02-335596
P407
P577
2011-05-09T00:00:00Z